Home Alzheimer’s Disease Amir Goldkorn, MD Discusses Baseline CTC Count as a Prognostic Marker of...

Amir Goldkorn, MD Discusses Baseline CTC Count as a Prognostic Marker of PSA Response and Progression in mCSPC

Data analysis of the SWOG S1216 trial showed that men with undetectable circulating tumor counts (CTCs) were 6.1-fold more likely to have a complete response to hormonal therapy and 3.7-fold more likely to achieve 2-years progression-free survival (PFS), according to study findings presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.

Amir Goldkorn, MD, an associate professor of medicine at the University of Southern California Keck School of Medicine spoke with CancerNetwork about the results of the trial.



So, this was a study that was conducted in the context of a large phase III randomized clinical trial called S1216. It’s a trial run by the NCI Southwest Oncology Group, or SWOG, a multicenter study. The PI on the clinical trial aspect is Dr. Neeraj Agarwal of the University of Utah, and in this trial 1200 men were…

Continue Reading to the Source


Please enter your comment!
Please enter your name here

Most Popular

please help us fundraise (501c3 non-profit) : braincancer

I work with OurBrainBank, a start-up non-profit dedicated to moving glioblastoma from terminal to treatable, powered by patients.We're a registered 501c3 non-profit in the...

Cancer and Mental Health Re-post : braincancer

Hello!I would like to thank everyone who participated in my survey these past few months! I received a tremendous response and I truly, truly...

Recent Comments